GTG secures new BREVAGen contracts

Genetic Technologies (ASX:GTG) has announced that up to six new US breast centres will start offering the company’s BREVAGenplus breast cancer risk assessment tool this calendar quarter.

The company expects a number of new breast diagnosis, imaging and treatment centres to pick up the test later the year, and so is anticipating an acceleration of sales growth starting in the second half.

Genetic Technologies recently completed a restructuring of its operations that involved selling its Australian genetics business and refocusing on sales to large comprehensive breast treatment and imaging centres.

BREVAGenplus launched in October. It is an upgraded version of the company’s BREVAGen test that is compatible with black and Hispanic women as well as Caucasians.

Genetic Technologies separately revealed that non-executive director David Carter has passed away.

“Our company is deeply saddened by the early passing of Mr David Carter,” Genetic Technologies said in a statement. “David will always be remembered fondly and we feel privileged to have had the pleasure of working with such a learned and warm person.”

Genetic Technologies (ASX:GTG) shares were trading 108.3% higher at $0.025 as of around 1 pm on Friday.